Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Furosemide

Preparation Calculator

USE IF: Volume overload, edema (HF/CKD/cirrhosis), acute pulmonary edema, adjunct-resistant HTN (with monitoring).

AVOID IF: Anuria; uncorrected severe electrolyte depletion; sulfa hypersensitivity when formulation relevant.

Furosemide

Loop diuretic

AdultDiureticHFRenalHTNEdema

Indication

Edema (HF/renal/hepatic), acute pulmonary edema, HTN (adjunct)

At a glance

INDICATIONS (CORE USE)

Edema (HF, CKD, cirrhosis), acute pulmonary edema, resistant HTN (adjunct); hyperkalemia — adjunct only when volume status and renal function permit; not definitive therapy.

ADULT DOSE (STANDARD)

PO: 20–40 mg start → titrate to urine output and congestion. IV: 20–40 mg → repeat/escalate; acute pulmonary edema: IV bolus ± infusion per protocol.

MAX DOSE

Variable — can exceed 600 mg/day in resistant states under close monitoring (electrolytes, renal function, perfusion).

Route

PO / IV

PEDIATRIC DOSE

Specialist weight-based protocols only.

Do not miss

Must-not-miss safety points

Major warning

- Hypokalemia / electrolyte depletion → arrhythmia risk - Over-diuresis → AKI / hypotension - Ototoxicity with high dose / rapid IV administration - Diuretic resistance → repeated ineffective low dosing is unsafe

Indications

USE IF: edema and congestion from HF/CKD/cirrhosis, acute pulmonary edema, adjunct-resistant HTN. AVOID IF: anuria, uncorrected severe electrolyte depletion, or sulfa allergy when product cross-reactivity matters.

Primary

  • Acute decompensated HF (IV)
  • Chronic edema (HF, CKD, cirrhosis)
  • Acute pulmonary edema

Secondary

  • Resistant hypertension (adjunct)
  • Hyperkalemia — adjunct only when volume status and renal function permit; not definitive therapy

Dosing

STANDARD (ADULT PO)

Start low → titrate to urine output, weight, and congestion endpoints.

ADULT DOSE

PO: 20–40 mg daily → titrate. IV: 20–40 mg → double dose if inadequate response (log dose–response). ICU: IV infusion for refractory volume overload per protocol.

PEDIATRIC DOSE

Specialist only.

MAX DOSE

Highly variable; >600 mg/day possible in refractory states with intensive monitoring.

Practical Note

CKD often needs higher threshold doses. **Cirrhosis / ascites (loop + spironolactone):** - Spironolactone is first-line; furosemide is commonly added for natriuresis and K balance — **not** an automatic mandate to pair every patient - Typical **protocol reference**: spironolactone : furosemide ≈ 100 : 40 — **not** a universal dosing formula - Loop may be added when spironolactone alone is insufficient - Titrate on **K⁺, Cr, weight/volume** after changes; reassess early when co-prescribed **HF / other edema:** - Loop + MRA may appear in **selected** refractory congestion — **not** a routine fixed-ratio rule outside cirrhosis pathways - Do **not** extrapolate cirrhosis ratio logic to all HF/edema care **Combo risks:** AKI, hypotension, electrolyte shifts — loop tends to lower K, MRA tends to raise K (labs drive adjustment).

Warnings

Clinical warnings

  • - Electrolyte depletion (K, Na, Mg)
  • - AKI from over-diuresis
  • - Hypotension / volume collapse
  • - Ototoxicity risk with high IV exposure
  • - Loop + spironolactone increases AKI, hypotension, and electrolyte-shift risk — reassess K⁺/Cr and volume after changes

Adverse effects

  • - Hypokalemia, hyponatremia, metabolic alkalosis
  • - Hypotension, dizziness
  • - Tinnitus / hearing loss (often dose- and rate-related IV)
  • - Hyperuricemia, rash (uncommon)

Contraindications

  • - Anuria
  • - Severe electrolyte depletion (uncorrected)
  • - Hypersensitivity (sulfonamide caution with formulation-dependent risk)

Drug interactions

  • - Digoxin + hypokalemia-mediated arrhythmia risk
  • - Aminoglycosides + ototoxicity risk
  • - ACEi/ARB + hypotension / AKI risk
  • - NSAIDs + diuretic resistance / AKI risk
  • - Spironolactone / MRAs / K-sparing diuretics → K⁺ and renal trajectory can swing either way — **lab-guided** titration; the cirrhosis ≈100:40 pairing is a **reference strategy**, not an automatic safe dose pair

Special populations

Pediatrics

Specialist weight-based protocols only.

Pregnancy

Pregnancy/

Lactation

use only when benefit outweighs risk per specialist and labeling.

Renal impairment

Expect higher dose requirements in CKD; track creatinine and electrolytes with every change.

Hepatic impairment

Ascites/cirrhosis: spironolactone first-line; add furosemide per pathway using ≈100:40 **protocol reference** (not a universal ratio); avoid over-diuresis / perfusion collapse.

Elderly

Higher hypotension and electrolyte swing risk — start conservative and reassess frequently.

Administration

PO: consistent timing; IV push slowly unless protocol specifies otherwise; high-dose or continuous infusion requires monitoring bundle (BP, I/O, labs, hearing symptoms).

Monitoring

  • Monitor: - Volume status (weight, urine output) - Electrolytes (K, Na, Mg) — K trend especially with MRA / K-sparing co-therapy - Renal function (Cr)
  • Recheck: - Within 1–2 weeks after outpatient dose change - Earlier reassessment of K⁺/Cr and volume after changes with spironolactone or other MRA/K-sparing (protocol-guided) - Daily labs if inpatient / ICU - If inadequate response in monitored setting, reassess dose adequacy / resistance
  • Hold if:
    - Severe hypokalemia
    - AKI / rising creatinine from over-diuresis
    - Symptomatic hypotension

Overdose / toxicity

Clinical Picture

Severe dehydration; electrolyte derangement; AKI; hypotension; ototoxicity if applicable.

Immediate Actions

Stop drug; supportive IV fluids as appropriate; correct electrolytes.

Antidote

No specific antidote — supportive care

Decontamination

Large recent oral ingestion: consider activated charcoal only if appropriate and airway-protected; otherwise supportive care per toxicology.

Escalation

ICU if refractory hypotension, severe arrhythmia, seizures, or severe AKI/electrolyte collapse. Consider renal replacement therapy if indicated.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Titrate to congestion/perfusion — not a fixed dose; every change needs electrolyte + renal plan. + Spironolactone: **cirrhotic ascites** pathways use ≈100:40 as **protocol reference** only — not routine HF/edema logic; pairing ↑ AKI / hypotension / K shifts — **lab-guided** titration.

Clinical pearls

*Furosemide + spironolactone (when combined):* first-line context is **cirrhotic ascites** (spironolactone-led); loop added for natriuresis/K dynamics — **not** a public “ratio calculator” and **not** required for every loop prescription. *Furosemide:* renally cleared — dose–response shifts in CKD; IV onset faster than PO for the same mg dose. *Loop diuretics (class):* - Loop dose-response is **logarithmic**. - If no response, **do not repeat** the same ineffective dose. - **Escalate** dose appropriately, consider **IV** route, or add **thiazide-type** sequential nephron blockade per protocol.

Loop diuretic safety

  • Recheck K/Mg after aggressive or prolonged IV use
  • Coordinate rapid high-dose IV pushes with pharmacy / protocol
  • With spironolactone/MRA: early K⁺/Cr + weight/volume reassessment after dose changes — protocol-guided, not ratio-autopilot

Pharmacy Tool

Preparation Calculator

Furosemide 10 mg/mL oral suspension

suspension · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

Onset minutes (IV) vs ~1 h (PO); elimination predominantly renal — effect and dose needs change with renal function.

Mechanism of action

Inhibits Na–K–2Cl cotransporter in the thick ascending limb of Henle → saluresis and free-water clearance.

Common brand names

Saudi Arabia

Lasix, Furosemide, Diurex

Global

(placeholder — verify local formulation)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Acute **pulmonary edema** and **refractory congestion** are **protocol- and team-driven** — targets, infusion choice, and escalation are **site-specific**.
  • Diuretic **response** varies with **renal perfusion**, **albumin**, and **concomitant nephrotoxins** — reassess endpoints frequently.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / HFSA heart failure guidance
  • KDIGO CKD blood pressure and diuretic use (where applicable)
  • FDA / SFDA product labeling
  • Institutional ICU / pharmacy compounding protocols when relevant
  • ACC / AHA / HFSA heart failure guidance
  • KDIGO CKD blood pressure and diuretic use (where applicable)
  • FDA / SFDA product labeling
  • Institutional ICU / pharmacy compounding protocols when relevant